BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30018131)

  • 21. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
    Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
    Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological features and prognoses in younger and older patients with mismatch repair defects colorectal cancer: a retrospective comparative cohort study.
    Zhang J; Li S; Ma P; Zhang J; Cao Y; Liu C; Zhang X; Li Z; Li C; Zhao Y
    J Gastrointest Oncol; 2024 Feb; 15(1):260-270. PubMed ID: 38482236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability.
    Svrcek M; El-Bchiri J; Chalastanis A; Capel E; Dumont S; Buhard O; Oliveira C; Seruca R; Bossard C; Mosnier JF; Berger F; Leteurtre E; Lavergne-Slove A; Chenard MP; Hamelin R; Cosnes J; Beaugerie L; Tiret E; Duval A; Fléjou JF
    J Clin Oncol; 2007 Sep; 25(27):4231-8. PubMed ID: 17878476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer.
    Jin HY; Liu X; Li VK; Ding Y; Yang B; Geng J; Lai R; Ding S; Ni M; Zhao R
    BMC Cancer; 2008 Feb; 8():44. PubMed ID: 18257912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.
    Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK
    Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
    Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
    Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
    Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
    Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
    BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Familial colorectal cancer type X: clinical, pathological and molecular characterization].
    Ferreira S; Lage P; Sousa R; Claro I; Francisco I; Filipe B; Suspiro A; Chaves P; Rodrigues P; Albuquerque C; Nobre Leitão C
    Acta Med Port; 2009; 22(3):207-14. PubMed ID: 19686620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer.
    Zhou Z; Li K; Wei Q; Chen L; Shuai Y; Wang Y; He K; Si L; Zhong Y; Lu J
    J Gastrointest Oncol; 2021 Dec; 12(6):2775-2787. PubMed ID: 35070406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microsatellite instability: an update.
    Yamamoto H; Imai K
    Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
    Lawes DA; Pearson T; Sengupta S; Boulos PB
    Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
    Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
    J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
    Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
    Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenomatous Polyposis Coli, mismatch repair, and microsatellite instability in colorectal cancer based on different locations.
    Effendi-Y S R; Zain LH; Siregar GA; Lubis HR; Damanik HA; Laksmi LI; Chrestella J
    Acta Med Indones; 2013 Oct; 45(4):275-83. PubMed ID: 24448331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma.
    Stein MK; Williard FW; Xiu J; Tsao MW; Martin MG; Deschner BW; Dickson PV; Glazer ES; Yakoub D; Shibata D; Grothey AF; Philip PA; Hwang JJ; Shields AF; Marshall JL; Korn WM; Lenz HJ; Deneve JL
    J Surg Oncol; 2020 Jun; 121(8):1320-1328. PubMed ID: 32166754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
    Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
    Front Immunol; 2022; 13():974793. PubMed ID: 36700211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.